

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

ALEXION PHARMACEUTICALS INC
Form 8-K
March 26, 2002

SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) MARCH 19, 2002

ALEXION PHARMACEUTICALS, INC.

(Exact Name of Registrant as Specified in its Charter)

DELAWARE	0-27756	13-3648318
-----	-----	-----
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)
352 KNOTTER DRIVE CHESHIRE, CT		06410
(Address of Principal Executive Offices)		(Zip Code)

Registrant's telephone number, including area code: (203) 272-2596

NOT APPLICABLE

(Former Name or Former Address, if Changed Since Last Report)

ITEM 5. OTHER EVENTS

On March 19, 2002, Alexion Pharmaceuticals, Inc. issued the press release filed herewith as Exhibit 99.1 regarding the promotion of David W. Keiser to President, Chief Operating Officer and Director of the Company.

ITEM 7. FINANCIAL STATEMENTS, PRO FORMA FINANCIAL INFORMATION AND EXHIBITS.

(c) EXHIBITS.

99.1 Press Release dated March 19, 2002.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

ALEXION PHARMACEUTICALS, INC.

Date: March 26, 2002

By: /s/ Leonard Bell

Name: Leonard Bell, M.D.
Title: Chief Executive Officer,

Edgar Filing: ALEXION PHARMACEUTICALS INC - Form 8-K

Secretary and Treasurer

EXHIBIT INDEX

99.1 Press Release dated March 19, 2002.